Ludwig N. Hantson
   HOME
*





Ludwig N. Hantson
Ludwig Norbert Michel Hantson (born August 1962) is a Belgium businessman, the CEO of Alexion Pharmaceuticals since March 2017. He was the president and CEO of Baxalta, an American biopharmaceutical company, from 2015 to 2016. Early life Hantson received a PhD in Motor Rehabilitation and Physical Therapy from the Université catholique de Louvain, University of Louvain in Belgium. Career Hantson was corporate vice president and president, international of Baxter from May 2010, before becoming CEO of Baxalta from July 2015, when Baxalta was spun off by its parent company, Baxter International until the finalization of Baxalta's acquisition a year later (completed June 2016) by Shire (pharmaceutical company), Shire. It was reported in January 2016 that Hantson's exit package, in cash and Shire stock, could be more than $30 million. In March 2017, Alexion Pharmaceuticals named Hantson as its CEO. In September 2017, Hantson relocated Alexion Pharmaceuticals's headquarters to Mass ...
[...More Info...]      
[...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  


Alexion Pharmaceuticals
Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became an independent subsidiary of AstraZeneca in 2021. Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in 2020 revenues, used to treat hypophosphatasia; sebelipase alfa (Kanuma) with $117 million in 2020 revenues, used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa) with $78 million in 2020 revenues, used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban. With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive dru ...
[...More Info...]      
[...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  



MORE